Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesEconomic Evaluation and Cost-Effectiveness Thresholds: Signals to Firms and Implications for R&D Investment and Innovation
PharmacoEconomics, 10/07/09
Vernon JA et al. – Thresholds set too low will result in R&D investment levels that are too low relative to the economic value of R&D. Similarly, thresholds set too high will result in inefficiently high levels of R&D spending. The US in particular, which represents approximately half of the global pharmaceutical market, and which seems poised to begin undertaking cost effectiveness in a systematic way, needs to exert caution in setting policies that explicitly or implicitly establish cost–effectiveness reimbursement thresholds for healthcare products and technologies, such as pharmaceuticals.
Today in Pharmacoeconomics...keeping you current
Receive free subspecialty "5-minute updates" via email
Treatment of Very Early Rheumatoid Arthritis With Symptomatic Therapy, Disease-Modifying Antirheumatic Drugs, or Biologic Agents. A Cost-Effectiveness Analysis
Annals of Internal Medicine, 11/03/09
Societal cost of rheumatoid arthritis patients in the US
Current Medical Research and Opinion, 11/13/09
Economic evaluation of doripenem for the treatment of nosocomial pneumonia in the US: discrete event simulation
Current Medical Research and Opinion, 11/13/09
Sponsor
Article Search
Sponsor